TNP 2500

Drug Profile

TNP 2500

Alternative Names: TNP2500

Latest Information Update: 14 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cumbre Pharmaceuticals
  • Developer TenNor Therapeutics
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections
  • Discontinued Tuberculosis

Most Recent Events

  • 14 Sep 2016 TenNor Therapeutics has patent protection for dual-acting molecules, including TNP 2500 in USA (TenNor Therapeutics website; September 2016)
  • 14 Sep 2016 Early research in Bacterial infections in China (unspecified route) (TenNor Therapeutics pipeline; September 2016)
  • 29 Sep 2006 The Global Alliance for TB Drug Development (TB Alliance) have the exclusive worldwide rights to compounds from this programme for the treatment of tuberculosis and other neglected diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top